口服替吉奥在晚期消化道肿瘤维持化疗安全性观察与疗效分析  

Safety Observation and Curative Effect Analysis of Maintenance Chemotherapy with Oral S-1 in Advanced Gastrointestinal Cancer

作　　者：詹颖[1,2] 陈巧慧[1,2] 江冬容 孙畋[1,2] 阙小梅[1,2] 许香贵[1,2] 

机构地区：[1]福建省龙岩市肿瘤研究所 [2]龙岩市第二医院肿瘤内科,龙岩364000

出　　处：《中国医药导刊》2013年第11期1834-1835,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:观察口服替吉奥作为晚期消化道肿瘤维持化学治疗(化疗)的耐受性和近期疗效。方法:对30例有可测量病灶晚期消化道肿瘤采用标准剂量替吉奥口服,观察其不良反应和近期疗效。结果:白细胞减少发生率30.0%,恶心呕吐发生率23.3%,不良反应发生率低;30例中,CR1例,PR9例,客观有效率(RR)33.3%,疾病控制率(DCR)为53.3%。结论:口服替吉奥在晚期消化道肿瘤维持化疗耐受性好,安全、方便,近期疗效确切。Objective：To investigate drug tolerance and short term effect of advanced gastrointestinal cancer treated by maintenance chemotherapy with oral S-1.Methods：A total of 30 patients with advanced gastrointestinal cancer who had measurable tumor lesions were treated with full dose of oral S-1.The adverse reactions were carefully observed and recent curative effect was evaluated in time.Results：In safety analysis,30%of the cases was leucopenia and 23.3%of the cases were nausea and vomiting.The incidence of adverse reactions is low.Of all patients,the complete response（CR） was 1 case,partial response（PR） was in 9 cases,and the objective response rate（PR） and disease control rate（DCR） were 33.3%and 53.3%,respectively.Conclusion：The oral S-1 is a well-tolerated,safe,convenient and highly effective maintenance chemotherapeutic regimen in advanced gastrointestinal cancer.

关 键 词：替吉奥 晚期消化道肿瘤 化疗 毒性 S-1 

分 类 号：R735[医药卫生—肿瘤]